BigSur Wealth Management LLC Reduces Stock Position in Danaher Co. (NYSE:DHR)

BigSur Wealth Management LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,675 shares of the conglomerate’s stock after selling 60 shares during the period. Danaher comprises approximately 1.0% of BigSur Wealth Management LLC’s holdings, making the stock its 29th largest holding. BigSur Wealth Management LLC’s holdings in Danaher were worth $3,373,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the fourth quarter valued at about $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher during the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. bought a new position in shares of Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher in the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher during the third quarter valued at approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $238.41 on Monday. The firm has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a one year low of $222.53 and a one year high of $281.70. The business has a fifty day moving average of $234.85 and a 200 day moving average of $253.42.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company posted $2.02 EPS. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 7.49 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s payout ratio is presently 20.61%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective for the company. TD Cowen lifted their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Citigroup lowered their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, KeyCorp upped their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.